USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
XERIS PHARMACEUTICALS, INC.
Address:
3208 Red River Street
Suite 300
Austin, TX 78705-
Phone:
N/A
URL:
N/A
EIN:
120335242
DUNS:
609377135
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,179,571.00 3
SBIR Phase II $1,707,856.00 2

Award List:

IMPROVED HYPOGLYCEMIA RESCUE DEVICE

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$157,478.00
Agency:
HHS
Principal Investigator:
John Kinzell
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to develop of a clinical prototype, semi-solid drug formulation and auto-injector pen that deliver microliter volumes of a glucagon dose without reconstitution for hypoglycemic emergenci es. To assess the feasibility of this… More

Improved Hypoglycemia Rescue Device

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$994,123.00
Agency:
HHS
Principal Investigator:
John Kinzell – 415-472-4623
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to demonstrate the safety, pharmacokinetics and initial efficacy of a ready-to-use Glucagon Rescue Pen that will deliver a very low volume dose of a glucagon without reconstitution for hypoglycemic emergencies. To execute on this… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$343,124.00
Agency:
HHS
Principal Investigator:
Steven Prestrelski – 510-742-9700
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of glucagon to the… More

Development of an Electromyographically Controlled Electrolarynx Voice Prosthesis

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$678,969.00
Agency:
HHS
Principal Investigator:
John Kinzell – 888-570-4781
Abstract:
DESCRIPTION (provided by applicant): The program outlined in this application has been designed to accelerate the development and commercialization of a Glucagon Mini-Dose Pen to change the paradigm for treatment of moderate hypoglycemia in insulin-using diabetics. This research is directly relevant… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$713,733.00
Agency:
HHS
Principal Investigator:
Steven Prestrelski – 858-414-1014
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of glucagon to the… More